Whether by snail mail, email, or social media, it’s the time of year for catching up with family and friends. As NIH Director, I’m also fortunate to hear from some of the amazing people who’ve been helped by NIH research. Among the greetings to arrive in my inbox this holiday season is this incredible video from a 15-year-old named Aaron, who is fortunate enough to count two states—Alabama and Colorado—as his home.
As a young boy, Aaron was naturally athletic, speeding around the baseball diamond and competing on the ski slopes in freestyle mogul. But around the age of 10, Aaron noticed something strange. He couldn’t move as fast as usual. Aaron pushed himself to get back up to speed, but his muscles grew progressively weaker.
Tags: anti-HMGCR myopathy, antibodies, autoimmunity, childhood diseases, clinical research, clinical trials, immunology, intravenous immunoglobulins, IVIG, muscle, muscle diseases, muscular dystrophy, myopathy, statins
For Salmonella and many other disease-causing bacteria that find their way into our bodies, infection begins with a poke. That’s because these bad bugs are equipped with a needle-like protein filament that punctures the outer membrane of human cells and then, like a syringe, injects dozens of toxic proteins that help them replicate.
Cammie Lesser at Massachusetts General Hospital and Harvard Medical School, Cambridge, and her colleagues are now on a mission to bioengineer strains of bacteria that don’t cause disease to make these same syringes, called type III secretion systems. The goal is to use such “good” bacteria to deliver therapeutic molecules, rather than toxins, to human cells. Their first target is the gastrointestinal tract, where they hope to knock out hard-to-beat bacterial infections or to relieve the chronic inflammation that comes with inflammatory bowel disease (IBD).
Tags: antibodies, bacteria, bacterial toxins, bioengineering, digestion, drug delivery, drug delivery vehicles, E. coli, Escherichia coli, gastrointestinal tract, IBD, inflammation, inflammatory bowel disease, intestine, microbiology, NIH Director’s 2016 Transformative Research Award, probiotics, secretion system, Shigella, single-domain antibodies, synthetic biology, technology, type III secretion systems
Recent research has shown that the mosquito-borne Zika virus has the potential to cause serious health problems, including severe birth defects in humans. But the damaging effects of Zika might not end there: results of a new mouse study show that the virus may also have an unexpected negative—and possibly long-lasting—impact on male fertility.
In work published in the journal Nature, an NIH-funded research team found that Zika infections can persist for many weeks in the reproductive systems of male mice . As a result of this infection, levels of testosterone and other sex hormones drop, sperm counts fall, and, in some animals, the testicles shrink to 1/10th of their normal size, possibly irreversibly. All of this adds up to Zika-infected male mice that are significantly less fertile than their healthy counterparts—producing about a quarter as many viable offspring as normal when mated with female mice. While mice are certainly not humans, the results underscore the urgent need for additional research to examine the full spectrum of Zika’s health effects in men, women, and children of both sexes.
Tags: antibodies, dengue virus, fertility, Guillain-Barré syndrome, infectious disease, inhibin B, male fertility, male reproductive system, male reproductive tract, male sex hormones, men, men's health, mosquito, mosquito-borne illnesses, pregnancy, primary spermatocytes, reproductive system, Sertoli cells, sperm, spermatogonia, testes, testicles, testosterone, virology, Zika, Zika virus